找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Statistical Methods in Biomarker and Early Clinical Development; Liang Fang,Cheng Su Book 2019 Springer Nature Switzerland AG 2019 Biomark

[复制链接]
楼主: microbe
发表于 2025-3-25 05:38:59 | 显示全部楼层
Predictive Subgroup/Biomarker Identification and Machine Learning Methods,ction for the right patients (with genomic or other types of biomarker). The next two chapters will discuss statistical methods pertinent to biomarkers that are the important ingredient in developing precision medicine.
发表于 2025-3-25 11:33:58 | 显示全部楼层
Characterize and Dichotomize a Continuous Biomarker,ients into groups (i.e., stratification or subgroup identification for tailoring). However, such categorization may result in significant loss of information. It is important that the analytical method evaluates and incorporates the continuum of biomarker values to guide the optimization of a clinic
发表于 2025-3-25 12:46:54 | 显示全部楼层
Surrogate Biomarkers,2558 million, according to a new study by the Tufts Center for the Study of Drug Development. The most critical stages of drug development are phase 2 and 3 development. One major reason that the average drug development cost is so high is that there are many failures in later phase clinical develop
发表于 2025-3-25 18:04:10 | 显示全部楼层
Innovative Designs for Biomarker-Guided Trials, a unique opportunity to guide clinical trial designs. Traditional clinical development of a novel therapy utilizes the “one-size-fits-all” approach by testing treatment effect in the entire patient population with a specific disease. It assumes that response in the disease population is homogeneous
发表于 2025-3-25 21:47:04 | 显示全部楼层
Statistical Considerations in the Development of Companion Diagnostic Device,le of personalized medicine is the approval of the drug Herceptin in patients with breast cancer who tested positive for human epidermal growth factor receptor 2 (HER2). This is also one of the earliest examples of a co-development drug and companion diagnostic (hereafter CDx) model before there was
发表于 2025-3-26 02:44:45 | 显示全部楼层
发表于 2025-3-26 05:59:11 | 显示全部楼层
发表于 2025-3-26 08:38:40 | 显示全部楼层
Clinical Application of Molecular Features in Therapeutic Selection and Drug Development,al validity, with an illustrating example of BRAF V600E for both aspects. In this chapter, we focus on a specific type of biomarkers: the ones useful for therapeutic decision and therapeutic drug development in the clinical setting.
发表于 2025-3-26 16:17:32 | 显示全部楼层
Big Data, Real-World Data, and Machine Learning, is limited when diagnosing complex polygenic human disease or guiding efficient treatment. Large-scale studies of gene expression have much more chance to capture the signal from human disease. Meanwhile, sequencing technology is rapidly advancing enabling us to evaluate millions of genomic feature
发表于 2025-3-26 19:05:18 | 显示全部楼层
Design and Analysis of Clinical Pharmacology Studies, tolerability of a new drug entity. These studies characterize the absorption, distribution, metabolism, and elimination of a drug in human body, and provide critical information for drug labeling. In this chapter, we will introduce different types of clinical pharmacology studies, their PK and safe
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-24 06:13
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表